Path
Nonprofit profile at a glance
- EIN
- 911157127
- IRS 990 coverage
- 2010–2025
- Official website data refreshed
- Sep 2026
- Forms available
- Form 990 2025
- Location
- Seattle, WA, USA
- Phone
- 2062853500
- Rating
- 86
- Verdict
- STRONG
- Rating confidence
- Standard
- Sector
- International Development
Reported finances
- Revenue
- $352,817,539
- Expenses
- $346,633,517
- Assets
- $335,091,155
- Liabilities
- $282,616,412
Source: IRS Form 990. Selected filing: tax year 2022. Amounts in USD.
Leadership & pay
33 people listed
Executive titles in this filing
- NIKOLAJ JESTED GILBERT MSC (PRESIDENT AND CEO)
Highest reported compensation
- NIKOLAJ JESTED GILBERT MSC (PRESIDENT AND CEO): $633,647 total reported compensation
- JOHN O KONZ PHD (GLOBAL HEAD OF POLIO): $429,560 total reported compensation
- DAVID C KASLOW MD (CHIEF SCIENTIFIC OFF. (UNTIL 10/8/22)): $420,354 total reported compensation
Source: IRS Form 990. Selected filing: tax year 2022. Names and roles reflect this filing, not necessarily current officeholders.
Overview
Mission
Our mission is to advance health access through innovation and partnerships. Our values These six values are essential to achieving our mission. We hold ourselves accountable to these values because they guide our behavior, decisions, and actions toward a future where good health is within reach for everyone. 1. **Respect**. We treat everyone with dignity, compassion, and appreciation.
What it reported doing in 2022
Essential medicines: path's essential medicines division develops and delivers lifesaving vaccines and drugs for women, children, and communities around the globe.(continued on schedule o)center for vaccine innovation and accesspath's center for vaccine innovation and access aligns expertise across every stage of vaccine research, development, and introduction to make vaccines available to more communities, particularly in lmics. Our portfolio includes more than two dozen vaccine products in development or already in use, with an emphasis on the leading infectious causes of child death and disease worldwide.in 2022, path continued to support the global covid-19 response by providing expertise to the covid-19 vaccines global access (covax) facility, supporting vaccine supply chain networks, providing technical assistance and training to vaccine manufacturers, strengthening country delivery readiness, and training pharmacists in ghana as vaccinators. We also coordinated grants to research groups conducting trials of covid-19 vaccines at fractional doses in low-resource settings. We supported the mrna vaccine technology hub in south africa and provided coordination and technical assistance for a consortium developing an egg-based covid-19 vaccine for production in brazil, thailand, vietnam, and other lmics. Additionally, we supported studies in australia, brazil, indonesia, mongolia, and pakistan. In ongoing efforts to facilitate local vaccine production, path supported lmic vaccine manufacturers to ready locally made vaccines for the global market, thereby increasing available interventions and potentially making vaccines more accessible for lmics. We provided technical assistance to several manufacturers preparing for who prequalification submission or inspection; supported manufacturers in clinical trial design and regulatory filings; began mapping the current vaccine manufacturing capacity in africa; and supported clinical assay development and technology transfers, among other activities. Path continued to provide technical support to polio vaccine manufacturers and advance research on new inactivated polio vaccine and oral polio vaccine candidates. In 2022, path disseminated collaborative study results on universal reagents for sabin inactivated polio vaccines. Throughout the year, path and our partners expanded coverage of japanese encephalitis (je) vaccination and developed and disseminated evidence to support je vaccine decision-making. Path continued studies on the cost of illness for je and its long-term consequences in bangladesh, laos, and vietnam. Path worked closely with the government of bangladesh and local partners to inform the country's je vaccination decision-making and submitted an application for je vaccine introduction to gavi, the vaccine alliance, in september 2022. Introduction of je vaccine in bangladesh is anticipated in 2025.also in 2022, we completed a pivotal phase 3 study of a polyvalent meningococcal meningitis conjugate vaccine (mmcv). This vaccine, developed by serum institute of india pvt. Ltd., builds on the success of menafrivac, a groundbreaking vaccine against serogroup a meningococcal meningitis that was developed through an earlier path partnership. The polyvalent vaccine targets serogroups a, c, w, x, and y. As the first vaccine to target serogroup x, the vaccine has the potential to eliminate meningococcal meningitis epidemics from africa's "meningitis belt" region. We continued to contribute technical and strategic expertise to the global defeating meningitis by 2030 initiative and supported the rollout of defeating meningitis by 2030: a global road map. Path also served as a coordinator between who, gavi, and global partners to identify pathways to accelerate mmcv introduction once the vaccine is made available. Path accelerated the development and introduction of a wide variety of malaria vaccine candidates and approaches. We continued to work with who; the ministries of health in g
Operating model
- Revenue model
- Donor-supported. 61% of the money available for current operations came from contributions and gifts.
- Distribution model
- Hybrid. The nonprofit split its reported program spending across 71% for direct work, and 29% for grants.
- Includes noncash contributions: Reported contributions include donated property or goods.
The verdict
STRONG - A large share of available resources goes toward mission work and the filed numbers largely add up. Expenses are high relative to revenue and assets have declined or grown slowly.
Rating breakdown
- Financial Efficiency: 88
- Transparency & Controls: 81
- Accountability: 100
- Sustainability: 43
- Growth: 80
Detailed rating inputs
Financial Efficiency
- Mission deployment rate: 88.4%; rating input score 88
- Program expense ratio: 89.8%; rating input score 90
- Fundraising efficiency: $138.5 raised per $1 spent on fundraising; rating input score 86; 86th percentile among comparable filings
Transparency & Controls
- Consistency checks: 100%; rating input score 100; 68th percentile among comparable filings
- Pay-setting controls: 4 of 6 controls in place; rating input score 67
- Compensation committee: Pass
- Independent consultant: Pass
- Other Form 990s reviewed: Missing
- Written employment contract: Missing
- Compensation survey or study: Pass
- Board or committee approval: Pass
- Foreign activity oversight: 2 of 8 controls in place; rating input score 25
- Claims monitoring procedures: Pass
- Requires narrative reports: Limited
- Conducts field audits: Limited
- May suspend future funding: Limited
- Requires financial reports: Limited
- Conducts site visits: Pass
- Requires grant agreements: Limited
- May require repayment: Limited
- Grant itemization coverage: 99.9%; rating input score 100; 49th percentile among comparable filings
- Major donor itemization: Yes; rating input score 100
- Related-party transparency: Yes; rating input score 100
Accountability
- Independent voting board: 100%; rating input score 100; 78th percentile among comparable filings
- Governance controls: 9 of 9 controls in place; rating input score 100
- Conflict-of-interest policy: Pass
- Whistleblower policy: Pass
- Document-retention policy: Pass
- CEO compensation review process: Pass
- Other executive compensation review process: Pass
- Form 990 shared with the board: Pass
- Board meeting minutes documented: Pass
- Audit committee oversight: Pass
- Independent financial-statement audit: Pass
Sustainability
- Operating margin: 1.8%; rating input score 48; 48th percentile among comparable filings
- Total-asset coverage ratio: 0.97; rating input score 39; 39th percentile among comparable filings
- Liabilities to assets ratio: 0.84; rating input score 15; 15th percentile among comparable filings
- Officer compensation ratio: 1.6%; rating input score 62; 62nd percentile among comparable filings
Growth
- Program expense growth: 3.3% per year; rating input score 100; 29th percentile among comparable filings
- Revenue growth: 4.8% per year; rating input score 100; 45th percentile among comparable filings
- Asset growth: -7.1% per year; rating input score 0; 2nd percentile among comparable filings
Details
- What they do: 9 programs and campaigns described on the official site · 2 operating locations identified
- Where the money goes: 88.4% of revenue deployed · 89.8% of spending went to programs
- Governance: 15 of 15 board members independent · 9 of 9 filing controls reported
- Programs: 4 filed program accomplishments · $311.4M in reported program spending
- Leadership: top reported pay $634K · 33 people listed · 4 of 6 pay-setting controls reported
- Highest-paid contractors: 5 contractors listed · $5.2M reported
- Consistency: 41 of 41 current checks pass
- Schedules: 11 filed schedules · includes major donors, foreign activity, grants, executive pay, and related organizations
- Filing history: 15 filing years from 2010 to 2025
- Contacts: How to reach this organization
- Money network: 55 filed money-flow records
- Related organizations: 40 filed related-organization links
- Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
- People: Everyone the filings name, and which of them the filings identify by more than a name.
- Staff and benefit plans: Retirement and health plans the organization files with the Department of Labor, and the people in them.
Key Signals
Signals prioritize questions for review. They are not findings of misconduct.
- Moderate — Sustainability: Operating margin scored 48/100.
- High — Growth: Asset growth scored 0/100.
- Moderate — Sustainability: Total-asset coverage ratio scored 39/100.
- High — Sustainability: Liabilities to assets ratio scored 15/100.